BMY - Heat Biologics' shares take off after HS-110-OPDIVO combo shines in mid-stage trial

Heat Biologics (HTBX) shares more than doubled in premarket trading after the company announces positive interim data from its Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's (BMY) OPDIVO (nivolumab) in advanced non-small cell lung cancer ((NSCLC)). HS-110 is an "off-the-shelf" allogeneic cell-based therapy designed to activate patients' immune system against multiple cancer testis antigens to elicit a diverse and robust immune response against tumor cells.Substantial survival benefit was observed in a cohort of previously treated, checkpoint inhibitor naïve patients with advanced NSCLC (Cohort A, N = 47).A median progression free survival ((PFS)) of 1.8 months and a median overall survival ((OS)) of 24.6 months was observed with a median follow-up time of 19.4 months.For NSCLC patients who had previously been treated with a checkpoint inhibitor and whose disease had subsequently progressed (Cohort B, N = 68), a median PFS of 2.8 months and median OS of 11.9 months was

For further details see:

Heat Biologics' shares take off after HS-110-OPDIVO combo shines in mid-stage trial